Phase I/ II Study of Pulmonary Suffusion to Control Minimal Residual Disease in Resectable or Ablatable Sarcoma or Colorectal Pulmonary Metastases
This phase I/II trial studies the side effects of pulmonary suffusion in controlling minimal residual disease in patients with sarcoma or colorectal carcinoma that has spread to the lungs. Pulmonary suffusion is a minimally invasive delivery of chemotherapeutic agents like cisplatin to lung tissues. Drugs used in chemotherapy, such as cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Pulmonary suffusion may also be useful in avoiding later use of drugs by vein that demonstrate no effect on tumors when delivered locally.
• Tumors metastatic to the lungs that are the focus of this protocol specifically:
‣ Soft tissue sarcoma
⁃ Osteosarcoma
⁃ Colorectal carcinoma
• Have an Eastern Cooperative Oncology Group (ECOG) performance status of =\< 2
• Hemoglobin \> 8.0 g/L
• Granulocytes \> 1,500 uL
• Platelets \>= 100,000 uL
• Creatinine clearance \>= 30 mL/min
• Clinically diagnosed resectable sarcoma lung metastases(while preregistration histologic or cytologic confirmation is desirable, this may not be required in clinical scenarios where a biopsy may not change the need to resect suspicious lung nodules or the biopsy itself poses a risk for tumor seeding. In such cases, the diagnosis will be supported by rapid pathologic evaluations intraoperatively before proceeding with Suffusion) Given the emergence of other acceptable options to destroy lung metastases such as SBRT or microwave ablation, a hybrid approach to eliminate all sites of disease will be permitted; however, supplemental approaches should be delayed, if possible, until after the 30 day post-suffusion endpoint
• Forced expiratory volume in 1 second (FEV1) \>= 50% predicted
• Diffusion capacity of the lung for carbon monoxide (DLCO) \>= 50% predicted
• Vital capacity (VC) \>= 50% predicted
• Ambulatory and resting oxygen (O2) saturation \> 88%
• Six minute walk \>= 50 % of the expected distance
• Surgeon affirmation that suffusion is technically feasible
• Borg Dyspnea scale (modified) \< 5
• Control of the primary tumor as determined by clinical assessment per standard of care; may include stable tumor status of primary tumor and other metastases, in the clinical judgement of the PI/Physician.
• Participants of child-bearing potential must agree to use adequate contraceptive methods (e.g., hormonal or barrier method of birth control; abstinence) prior to study entry. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately
• Participant must understand the investigational nature of this study and sign an Independent Ethics Committee/Institutional Review Board approved written informed consent form prior to receiving any study related procedure